Mortality and rebleeding following variceal haemorrhage in liver cirrhosis and periportal fibrosis

Table 2 Clinical findings and medical management provided in 94 patients with liver cirrhosis and periportal fibrosis presenting with acute variceal haemorrhage n (%)

Variable	PPF (n = 62)	Cirrhosis (n = 32)	P value
Jaundice	0 (0)	16 (50)	0.0001
Ascites	5 (8.1)	16 (50)	0.0001
Encephalopathy	3 (4.8)	9 (28.1)	0.0011
Child class A	-	9 (28)	-
Child class B	-	13 (41)	-
Child class C	-	10 (31)	-
MELD score < 18		19 (59.4)	-
MELD score > 18		13 (40.6)	-
PPF grade II	29	-	-
PPF grade III	71	-	-
Mean portal vein diameter	17.4 ± 3.3 mm	16.4 ± 3.1 mm	0.155
Terlipressin stat dose 2 mg IV	48 (77.4)	27 (84.4)	0.426
Terlipressin 6 hourly over 24 h	15 (24.2)	14 (43.8)	0.052
Requirement for blood transfusion (mean number of units)	2 ± 1 units	2 ± 1 units	-

¹Significant risk factor. PPF: Periportal fibrosis; MELD: Model for end stage liver disease.